1318780-07-2

Upstream product

• 897360-38-2 6-chloropyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 1036738-12-1 2,4,6-trichloropyrido[3,2-d]pyrimidine 
• 1203655-68-8 2,6-dichloro-N-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidin-4-amine 
• 1203655-86-0 3-(aminomethyl)-N-tert-butyl-5-(trifluoromethyl)benzenesulfonamide 
• 1318780-16-3 N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)phenyl)-1-(trifluoromethyl)cyclopropanecarboxamide 
• 1318780-12-9 N-tert-butyl-3-((6-chloro-4-(2,2,2-trifluoroethylamino)pyrido[3,2,d]pyrimidin-2-ylamino)methyl)-5-(trifluoromethyl)benzenesulfonamide 
• 1352577-51-5 C₃₂H₃₀F₉N₇O₃S 
• 1318780-17-4 N-tert-butyl-3-cyano-5-(trifluoromethyl)benzenesulfonamide 
• 175358-01-7 3-amino-6-chloro-pyridine-2-carboxylic acid amide 
• 277756-46-4 1-(trifluoromethyl)cyclopropanecarboxylic acid 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 

Relevant academic research and scientific papers

Optimization of pharmacokinetics through manipulation of physicochemical properties in a series of HCV inhibitors

A novel series of HCV replication inhibitors based on a pyrido[3,2-d]pyrimidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of comp